← Leaderboards
Ann E Sluder
Cambria Biosciences, Llc
$1,272,481
Attributed
$1,272,481
Total exposure
5
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,272,481 · 5
By mechanism
R44$746,396 · 1
R43$526,085 · 4
Top collaborators
No co-investigators on record.
Most similar at Cambria Biosciences, Llc
Same institution · by research overlap
- Bethany Westlund$1,543,095
- Satinder S Sarang$291,202
- Donald R. Kirsch$805,284
Others in their field
Top investigators on “Caenorhabditis Elegans”
- Paul Warren Sternberg · California Institute Of Technology$70,466,566
- Gary B. Ruvkun · Massachusetts General Hospital$34,445,663
- Monica A. Driscoll · Rutgers, The State Univ Of N.J.$28,359,225
- Robert H Waterston · Washington University$27,808,567
- Gordon J. Lithgow · Buck Institute For Age Research$27,627,681
- Albertha Johanna Walhout · Univ Of Massachusetts Med Sch Worcester$23,781,678
Research focus
Caenorhabditis ElegansHigh Throughput TechnologyAnthelminticsDrug Screening /EvaluationDrug Discovery /IsolationNuclear ReceptorsGenetic TranscriptionBinding SitesBioassayLigandsChimeric ProteinsProtein Structure FunctionTechnology /Technique DevelopmentFungal GeneticsHelminth GeneticsHost Organism InteractionInsulinIntermolecular InteractionMolecular CloningNematodaNeuroprotectantsNucleotidesPhenotypePolymerase Chain Reaction
Grant awards (6)
RILUZOLE MOA: TARGETS FOR IMPROVED NEUROPROTECTIVE DRUGS$253,798
R43 · FY2004 · NS
Development of nuclear receptors as anthelmintic targets$322,141
R44 · FY2003 · AI
Development of nuclear receptors as anthelmintic targets$424,255
R44 · FY2002 · AI
Chemical Genetics of a C. elegans Signaling Cascade$99,904
R43 · FY2002 · GM
DEVELOPMENT OF NUCLEAR RECEPTORS AS ANTHELMINTIC TARGETS$76,238
R43 · FY2001 · AI
C. ELEGANS SCREEN FOR NOVEL ANTI-NEMATODE DRUGS$96,145
R43 · FY2000 · AI